{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~36 mi. (Munich, Germany, +130 more cities)
facility
Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266)
drug
BCG solution, +1 more drug
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
city
~36 mi. (Munich, Germany, +3 more cities)
facility
Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum
biomarker
ER Positive, +2 more biomarkers
drug
hormone therapy, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
city
~36 mi. (Munich, Germany, +37 more cities)
facility
Klinikum Rechts der Isar der Technischen Universitat Munchen
biomarker
ER Negative, +2 more biomarkers
drug
ladiratuzumab vedotin, +1 more drug
drug type
chemotherapy, +2 more types
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~37 mi. (Gauting, Germany, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~73 mi. (Regensburg, Germany, +93 more cities)
facility
Caritas Krankenhaus St. Josef ( Site 0502)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types